Comment on

• Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.

  Pauly MP, Tucker LY, Szpakowski JL, Ready JB, Baer D, Hwang J, Lok AS. Pauly MP, et al. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1964-1973.e1. doi: 10.1016/j.cgh.2018.04.033. Epub 2018 Apr 24. Clin Gastroenterol Hepatol. 2018. PMID: 29702293
• The Risk of Hepatitis B Virus Reactivation in HBsAg-Negative and Anti-HBc-Positive Patients Receiving Tumor Necrosis Factor Antagonists.

  Ozaras R, Ozaras N, Demirel A. Ozaras R, et al. Clin Gastroenterol Hepatol. 2019 Jan;17(1):210. doi: 10.1016/j.cgh.2018.07.028. Clin Gastroenterol Hepatol. 2019. PMID: 30558892 No abstract available.